pulsatrix melanota Band-bellied Owl Systematics - Band-bellied Owl -

Comprehensive Support: Achieving sustainable weight loss requires more than just injectionsit requires ongoing support and guidance

Research classification: Selective growth hormone secretagogue (ghrelin receptor agonist)

doi:10.1056/NEJMoa2312323CrossRefGoogle ScholarPubMed Cukierman-Yaffe, T, Gerstein, HC, Colhoun, HM, et al

doi:10.1159/000275883 Giacosa A, Morazzoni P, Bombardelli E, Riva A, Bianchi Porro G, Rondanelli M

GLP1 + Cagrilintide Research Administration Common Study Populations Clinical trials have enrolled diverse participant groups: Adults with obesity BMI 30 kg/m squared or greater without diabetes (REDEFINE 1) Adults with overweight and comorbidities BMI 27 kg/m squared or greater with at least one weight-related condition Adults with type 2 diabetes BMI 27 kg/m squared or greater with established diabetes (REDEFINE 2) Age range Primarily adults aged 18-75 years across trials Geographic diversity Multi-national trials across North America, Europe, Asia, and other regions Exclusion criteria typically included type 1 diabetes, recent cardiovascular events, severe renal or hepatic impairment, history of pancreatitis, and medications causing significant weight changes